Back to GetFilings.com



Table of Contents

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 10-Q

 


 

(Mark One)

 

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For The Quarterly Period Ended March 31, 2004

 

OR

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission File Number: 0-19171

 


 

ICOS CORPORATION

(Exact name of registrant as specified in its charter)

 


 

Delaware   91-1463450

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

22021 - 20th Avenue S.E., Bothell, WA 98021

(Address of principal executive offices) (Zip code)

 

(425) 485-1900

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

 


 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

 

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).    Yes  x    No  ¨

 

Indicate the number of shares outstanding of each of the issuer’s classes of Common Stock, as of the latest practicable date.

 

Class


 

Outstanding at March 31, 2004


Common Stock, $0.01 par value

  63,337,601

 



Table of Contents

ICOS CORPORATION

FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2004

 

TABLE OF CONTENTS

 

     PAGE NO.

PART I. Financial Information

    
     ITEM 1.   Financial Statements     
         Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2004 and 2003    1
         Condensed Consolidated Balance Sheets as of March 31, 2004 and December 31, 2003    2
         Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2004 and 2003    3
         Notes to Condensed Consolidated Financial Statements    4
     ITEM 2.   Management’s Discussion and Analysis of Results of Operations and Financial Condition    7
     ITEM 3.   Quantitative and Qualitative Disclosures about Market Risk    29
     ITEM 4.   Controls and Procedures    29

PART II. Other Information

    
     ITEM 6.   Exhibits and Reports on Form 8-K    30

SIGNATURE

   31


Table of Contents

PART 1. Financial Information

 

ITEM 1. Financial Statements

 

ICOS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

(unaudited)

 

     Three Months Ended
March 31,


 
     2004

    2003

 

Revenue:

                

Collaboration revenue from related parties

   $ 14,067     $ 5,348  

Licenses of technology

     —         633  

Contract manufacturing

     2,456       1,100  
    


 


Total revenue

     16,523       7,081  
    


 


Operating expenses:

                

Research and development

     17,254       25,142  

Marketing and selling

     9,797       921  

Cost of contract manufacturing

     2,513       833  

General and administrative

     4,153       3,454  
    


 


Total operating expenses

     33,717       30,350  
    


 


Operating loss

     (17,194 )     (23,269 )

Other income (expense):

                

Equity in losses of Lilly ICOS

     (69,237 )     (21,547 )

Interest expense

     (1,711 )     —    

Interest and other income

     1,839       3,712  
    


 


Loss before income taxes

     (86,303 )     (41,104 )

Income tax recovery

     —         612  
    


 


Net loss

   $ (86,303 )   $ (40,492 )
    


 


Net loss per common share – basic and diluted

   $ (1.36 )   $ (0.65 )
    


 


Weighted-average common shares outstanding – basic and diluted

     63,237       62,174  
    


 


 

See accompanying notes to condensed consolidated financial statements.

 

1


Table of Contents

ICOS CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

(unaudited)

 

     March 31,
2004


    December 31,
2003


 
ASSETS                 

Current assets:

                

Cash and cash equivalents

   $ 278,187     $ 332,039  

Investment securities, at market value

     93,221       83,049  

Interest receivable

     2,224       2,668  

Receivables from affiliates

     18,410       17,681  

Note receivable

     —         6,000  

Other

     5,953       3,819  
    


 


Total current assets

     397,995       445,256  

Investment securities, at market value

     61,790       51,769  

Property and equipment, net

     18,709       18,970  

Deferred financing costs and other

     8,548       8,859  
    


 


     $ 487,042     $ 524,854  
    


 


LIABILITIES AND STOCKHOLDERS’ EQUITY                 

Current liabilities:

                

Payables and accruals

   $ 17,478     $ 17,476  

Accrued interest

     1,393       2,957  

Due to affiliates

     70,221       25,842  

Deferred revenue

     3,049       1,000  
    


 


Total current liabilities

     92,141       47,275  
    


 


Convertible subordinated debt

     278,650       278,650  
    


 


Stockholders’ equity:

                

Common stock

     633       630  

Additional paid-in capital

     790,781       787,019  

Accumulated other comprehensive income

     613       753  

Accumulated deficit

     (675,776 )     (589,473 )
    


 


Total stockholders’ equity

     116,251       198,929  
    


 


     $ 487,042     $ 524,854  
    


 


 

See accompanying notes to condensed consolidated financial statements.

 

2


Table of Contents

ICOS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(unaudited)

 

     Three Months Ended
March 31,


 
     2004

    2003

 

Cash flows from operating activities:

                

Net loss

   $ (86,303 )   $ (40,492 )

Adjustments to reconcile net loss to net cash used in operating activities:

                

Depreciation and amortization

     2,768       3,304  

Gain on sale of investment securities, net

     —         (1,290 )

Equity in losses of Lilly ICOS

     69,237       21,547  

Revenue collected greater (less) than revenue recognized

     2,049       (881 )

Change in operating assets and liabilities:

                

Receivables

     (553 )     227  

Payables and accruals

     (1,562 )     (5,171 )

Other assets

     (1,891 )     (1,385 )

Other

     119       199  
    


 


Net cash used in operating activities

     (16,136 )     (23,942 )
    


 


Cash flows from investing activities:

                

Purchases of investment securities

     (57,277 )     (19,167 )

Maturities of investment securities

     35,960       26,365  

Sales of investment securities

     —         88,991  

Acquisitions of property and equipment

     (1,212 )     (725 )

Collection of note receivable arising from sale of partnership interests

     6,000       —    

Investments in affiliates

     (24,858 )     (22,135 )
    


 


Net cash provided by (used in) investing activities

     (41,387 )     73,329  
    


 


Cash flows from financing activities:

                

Proceeds from stock options

     3,671       1,061  

Borrowings under line of credit

     —         2,069  
    


 


Net cash provided by financing activities

     3,671       3,130  
    


 


Net increase (decrease) in cash and cash equivalents

     (53,852 )     52,517  

Cash and cash equivalents, beginning of period

     332,039       40,450  
    


 


Cash and cash equivalents, end of period

   $ 278,187     $ 92,967  
    


 


Supplemental disclosure of cash flow information:

                

Debt forgiveness upon achievement of clinical milestone

   $ —       $ 3,055  
    


 


Income tax benefit receivable

   $ —       $ 612  
    


 


Interest payments on convertible subordinated debt

   $ 2,957     $ —    
    


 


 

See accompanying notes to condensed consolidated financial statements.

 

3


Table of Contents

ICOS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(In thousands, unless otherwise noted)

(unaudited)

 

1. Summary of Significant Accounting Policies

 

The accompanying condensed consolidated financial statements present the results of operations, financial position and cash flows of ICOS Corporation and its wholly-owned subsidiaries, herein collectively referred to as ICOS. All material intercompany transactions and balances between entities consolidated in these financial statements have been eliminated.

 

The accompanying condensed consolidated financial statements have not been audited. We have condensed or omitted certain information and footnote disclosures normally included in financial statements presented in accordance with accounting principles generally accepted in the United States. We believe the disclosures made are adequate to make the information presented not misleading. However, you should read these condensed consolidated financial statements in conjunction with the consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2003.

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Ultimate results could differ from those estimates.

 

In our opinion, the accompanying condensed consolidated financial statements include all adjustments, consisting only of normal recurring items, necessary to present fairly our financial position as of March 31, 2004 and December 31, 2003, and our results of operations and cash flows for the three months ended March 31, 2004 and 2003. Interim results are not necessarily indicative of results for a full year.

 

Stock Based Compensation

 

We apply the provisions of Accounting Principles Board (APB) Opinion No. 25, “Accounting for Stock Issued to Employees,” and related interpretations in accounting for our employee stock option grants. Accordingly, we do not recognize compensation expense for options granted to employees with an exercise price equal to or in excess of the fair value of the underlying common shares at the date of grant. We recognize compensation expense for restricted stock grants over the applicable vesting period.

 

4


Table of Contents

Had we determined compensation cost based on the fair value of our stock options on the grant date under Statement of Financial Accounting Standards No. 123, “Accounting for Stock Based Compensation,” our net loss and net loss per share would have been the following pro forma amounts:

 

     Three Months Ended
March 31,


 
     2004

    2003

 

Net loss:

                

As reported

   $ (86,303 )   $ (40,492 )

Add: Stock based employee compensation expense included in reported net loss

     69       69  

Deduct: Stock based employee compensation expense determined under fair value based method for all awards

     (9,041 )     (11,564 )
    


 


Pro forma

   $ (95,275 )   $ (51,987 )
    


 


Net loss per share—basic and diluted:

                

As reported

   $ (1.36 )   $ (0.65 )
    


 


Pro forma

   $ (1.51 )   $ (0.84 )
    


 


 

The estimated per share weighted-average grant date fair value of stock options awarded during the three months ended March 31, 2004 and 2003, was $27.67 and $13.79, respectively. Amounts were determined using the Black-Scholes option pricing model based on the following assumptions:

 

     Three Months Ended
March 31,


 
     2004

    2003

 

Expected dividend yield

   0.0 %   0.0 %

Risk-free interest rate

   3.4 %   3.3 %

Expected volatility

   68.1 %   67.9 %

Expected life in years

   6.6     6.4  

 

In March 2004, the Financial Accounting Standards Board issued an Exposure Draft of a proposed Statement of Financial Accounting Standards entitled “Share-Based Payment.” This proposed Statement addresses accounting for stock based compensation and would result in stock based compensation costs, including options, being recognized as an expense in the financial statements. The proposed Statement would eliminate the ability to account for stock based compensation transactions using APB Opinion No. 25, and generally would require that such transactions be accounted for using a fair value based method. If approved, the proposed statement would be applied to public entities, prospectively, for fiscal years beginning after December 15, 2004.

 

2. Revenue from Collaborations and Licenses of Technology

 

The following tables summarize our revenue from collaborations with related parties and licenses of technology for the three months ended March 31, 2004 and 2003.

 

     Three Months Ended
March 31,


     2004

   2003

Collaboration revenue from related parties:

             

Lilly ICOS LLC (Lilly ICOS)

   $ 14,067    $ 2,053

Sunc